Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C32H29NO5 |
Molecular Weight | 507.5764 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2CN([C@@H](CC2=C1OCC3=CC=CC=C3)C(O)=O)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5
InChI
InChIKey=GHBCIXGRCZIPNQ-MHZLTWQESA-N
InChI=1S/C32H29NO5/c1-37-28-18-17-25-20-33(31(34)29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)27(32(35)36)19-26(25)30(28)38-21-22-11-5-2-6-12-22/h2-18,27,29H,19-21H2,1H3,(H,35,36)/t27-/m0/s1
Molecular Formula | C32H29NO5 |
Molecular Weight | 507.5764 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Olodanrigan (EMA-401) is an angiotensin II type 2 receptor antagonist. Olodanrigan may act on paracrine/autocrine mechanisms at peripheral nerve terminals, or intracrine mechanisms, to reduce neuropathic pain signalling in AngII/NGF/TRPV1-convergent pathways. Olodanrigan is being developed by Novartis for the treatment of neuropathic pain.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28255254
A pilot phase IIa study demonstrated the efficacy and safety of the drug taken twice daily as two capsules of 50 mg (400 mg/day).
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:59:08 GMT 2023
by
admin
on
Sat Dec 16 07:59:08 GMT 2023
|
Record UNII |
P0FN522VTO
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1316755-16-4
Created by
admin on Sat Dec 16 07:59:08 GMT 2023 , Edited by admin on Sat Dec 16 07:59:08 GMT 2023
|
PRIMARY | |||
|
P0FN522VTO
Created by
admin on Sat Dec 16 07:59:08 GMT 2023 , Edited by admin on Sat Dec 16 07:59:08 GMT 2023
|
PRIMARY | |||
|
C174823
Created by
admin on Sat Dec 16 07:59:08 GMT 2023 , Edited by admin on Sat Dec 16 07:59:08 GMT 2023
|
PRIMARY | |||
|
100000177040
Created by
admin on Sat Dec 16 07:59:08 GMT 2023 , Edited by admin on Sat Dec 16 07:59:08 GMT 2023
|
PRIMARY | |||
|
9937291
Created by
admin on Sat Dec 16 07:59:08 GMT 2023 , Edited by admin on Sat Dec 16 07:59:08 GMT 2023
|
PRIMARY | |||
|
DTXSID101031601
Created by
admin on Sat Dec 16 07:59:08 GMT 2023 , Edited by admin on Sat Dec 16 07:59:08 GMT 2023
|
PRIMARY | |||
|
10476
Created by
admin on Sat Dec 16 07:59:08 GMT 2023 , Edited by admin on Sat Dec 16 07:59:08 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|